I don't agree with belly up comment because PACB has positive profit if you exclude R&D. R&D cost is high since it's still a new company.
I do agree though that PACB might be acquired buy bigger player...
These are probably granted through some predefined terms...If they buy with their $ then it's a bullish sign, not when it's granted.
If you believe (I do) that next decade will dominate the personalized medicine then it's one of the best stock to won.
Roche already invested 75M in Pacbio and exclusive right for diagnostic instrument. And Pacbio already passed phase 2, plan to release it in early 2016 as planned. We have to wait and see.
Nanopore might be good for small gene/segment detection but it has not demonstrated if they can assemble large organism.